A baby born with a Rare and dangerous genetic disease grows and prosperous after obtaining a Gene editing treatment Just made for him.
The researchers described the case in a new study, saying that it is among the first to be successfully treated with personalized therapy that seeks to correct a tiny but critical error in its genetic code which kills half of the affected infants. Although it may be a while before similar personalized treatments are available for others, doctors hope that technology will one day help the millions of people left, even if genetic medicine has progressed because their conditions are so rare.
“This is the first step towards the use of gene mounting therapies to treat a wide variety of rare genetic disorders for which there is currently no definitive medical treatment,” said Dr. Kiran Musunuru, an expert in gene publishing from Pennsylvania University who co-wrote the study published Thursday in the New England Journal of Medicine.
The baby, KJ Muldoon of Clifton Heights, Pennsylvania, is one of the 350 million people around the world of rare diseases, most of whom are genetic. It was diagnosed shortly after birth with a severe CPS1 deficiency, estimated by some experts to assign about one million over a million. These infants do not have a necessary enzyme to help eliminate ammonia from the body, so it can accumulate in their blood and become toxic. A liver transplant is an option for some.
Knowing the sides of KJ, the parents Kyle and Nicole Muldoon, both of 34, feared losing it.
“We were, as, you know, weigh all the options, asking all the questions for liver transplant, which is invasive, something that has never been done before,” said Nicole.
“We prayed, we talked to people, we collected information and we finally decided that it was that we were going to go,” added her husband.
In six months, the Philadelphia and Penn Medicine children’s hospital team, as well as their partners, created a therapy designed to correct KJ’s defective gene. They used CRISPR, the gene editing tool that won its inventors the Nobel Prize In 2020. Instead of cutting the DNA strand like the first CRISPR approaches, the doctors used a technique that returns the “letter” of mutated DNA – also known by the basic name – to the right type. Known as “basic assembly”, it reduces the risk of involuntary genetic changes.
It is “very exciting” that the team created therapy so quickly, said the researcher in gene therapy Senthil Bhoopalan at the research hospital for children St. Jude in Memphis, who was not involved in the study. “It really gives the pace and the reference for such approaches.”
In February, KJ obtained its first IV infusion with genetic edition therapy, delivered through tiny fatty droplets called lipid nanoparticles which are taken by liver cells.
While the play was in excitement of excitement that day, “he slept through all of this,” said the study author, Dre Rebecca Ahrens-Nicklas, expert in gene therapy in Chop.
After doses of follow -up in March and April, KJ was able to eat more normally and recovered well from diseases like colds, which can filter the body and exacerbate the symptoms of CPS1. The 9 and a half year old child also takes fewer medication.
Given his bad prognosis earlier, “each time we even see the smallest stage he meets – like a small wave or rolling – it’s a big moment for us,” said his mother.
However, researchers warn that it only takes a few months. They will have to look at him for years.
“We are still very in the early stages of understanding what this medication was able to do for KJ,” said Ahrens-Nicklas. “But every day, he shows us signs that he grows and prosperous.”
Researchers hope that what they learn from KJ will help other patients with rare diseases.
Genetic therapies, which can be extremely expensive to develop, generally target more common disorders for simple financial reasons: more patients potentially mean more sales, which can help pay development costs and generate more benefits. The first CRISPR therapy Approved by Food and Drug American AdministrationFor example, treats sickle cell anemia, a painful blood disorder affecting millions in the world.
Musunuru said his team’s work – Partly funded by the National Institutes of Health – has shown that creating personalized treatment should not be prohibitive. The cost was “not far” of $ 800,000 and more for an average liver transplantation and related care, he said.
“While we are getting better and better to do these therapies and further shorten the delay, the economies of scale will be hampered and I would expect costs to drop,” said Musunuru.
Scientists will not have to redo all the initial work each time they create personalized therapy, said Bhoopalan, so this research “prepares the way” to deal with other rare conditions.
Carlos Moraes, professor of neurology at the University of Miami who was not involved in the study, said that research like this one opens the door to more advances.
“Once someone came with a breakthrough like this, it will not take time” so that other teams apply the lessons and move forward, “he said. “There are obstacles, but I predict that they will be crossed over the next five to 10 years. Then, the whole field will move in block because we are almost ready.”
———-
The Department of Health and Sciences of the Associated Press receives the support of the scientific and educational group of the media from the medical institute Howard Hughes and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
